Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (AD);~* Has a Mini-Mental State Examination total score of 16 to 26;~* Has a Modified Hachinski Ischemia Scale score of ≤ 4;~* Is taking a stable dose of donepezil, galantamine or rivastigmine for at least 30 days;~* Has had a computerized tomography or magnetic resonance imaging. The scan must not show evidence for an alternative etiology for dementia;~* With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, is in general good health.~Exclusion Criteria:~* Positive screen for drugs of abuse, alcohol or cotinine;~* Females must not have positive results for pregnancy;~* Focal neurological signs on examination;~* Has a clinically significant abnormal value, in serum chemistry, hematology or urinalysis;~* History of any significant neurologic disease other than AD;~* History of head trauma, motor vehicle accident, concussion.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ABT-957 (Type: EXPERIMENTAL): ABT-957 administered twice-daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered twice-daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).